Alto Neuroscience (ANRO) Non-Current Debt (2023 - 2026)

Alto Neuroscience has disclosed Non-Current Debt across 4 years of filings, most recently posting $13.9 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $13.9 million, down 30.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.9 million (down 30.37% YoY), and the FY2025 annual result was $16.2 million, up 57.71% from the prior year.
• Non-Current Debt came in at $13.9 million for Q1 2026 at Alto Neuroscience, down from $16.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $20.3 million in Q3 2025 to a low of $6.6 million in Q3 2024.
• The 4-year median for Non-Current Debt is $12.1 million (2024), against an average of $13.4 million.
• Across the five-year window, Non-Current Debt soared 206.53% in 2025 and tumbled 30.37% in 2026, its largest moves.
• Alto Neuroscience's Non-Current Debt stood at $9.9 million in 2023, then climbed by 3.99% to $10.3 million in 2024, then soared by 57.71% to $16.2 million in 2025, then fell by 14.14% to $13.9 million in 2026.
• The last three Non-Current Debt figures came in at $13.9 million (Q1 2026), $16.2 million (Q4 2025), and $20.3 million (Q3 2025), per Business Quant data.